Conference Presentation, Panel
The Highs - and Lows - of the Cannabis Economy
Milken InstituteMike Zaplin, Todd Denkin, Craig Ellens, Sue Rouchet, Michael Kraft, Doug Praw, Deepak Chopra, Peter Janssen, Tommy Lasorda, Chief Justice Roberts, Greg
- The cannabis industry is projected to mature into a $50 to $100 billion sector moving from "pirates and outlaws" to a professionalized phase termed "Cannabis 2.0," with participants anticipating growth comparable to the automobile or oil industries.
- Institutional financing and pharmaceutical-level research are expected to drive the sector toward standardization, requiring consistent genetics, sterile growing environments, and rigorous testing for heavy metals, pesticides, and microbials to replace current testing limited to THC and CBD.
- Regulatory frameworks are predicted to shift the industry from cash-based operations to regulated systems potentially approved by the FDA or industry self-regulation, with a transition plan that includes state-chartered banks adhering to eight federal priorities.
- Significant risks include a potential tripling of marijuana abuse among children if controls fail, with projections that one in six users starting before age 18 will become addicted, leading to future driving and mental health complications similar to the tobacco industry's $206 billion in state payments.
- Industry evolution plans involve the establishment of trade schools to train "Bud Masters," the implementation of seed-to-sale software, and the development of vaporizers as the premier drug delivery system to ensure safety and prevent diversion.
- A "responsible approach" is advocated to avoid litigation pitfalls seen in other sectors, with a specific commitment from GrowBlock Science to dedicate 5% of retail sales to education and harm mitigation, alongside a move away from marketing flavored products to minors.
- Clinical-like research is expected to unlock major disease cures within a year, utilizing pharmaceutical standards where synthetic versions of ingredients may be approved if herbal plants are not directly approved by the FDA.
- Global market dynamics suggest Canada's regulated medicinal market will serve as a model for the U.S., while 32 states having already legislated use creates an interplay requiring local regulation and private financing to navigate federal constraints.
- The trajectory anticipates that current business players lacking proper standards will be replaced by a new generation of companies capable of meeting pharmaceutical industry requirements, driven by demand for consistent and reliable products.